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Abstract  
 
Objectives: Combined oral contraceptives (COCs) decrease testosterone (T) levels. This 
study investigated restoration of T and other androgen concentrations during COC use by co-
administration of dehydroepiandrosterone (DHEA). 
 
Study design: In this randomized, double-blind, placebo-controlled study in 99 new COC 
starters (18-35 years old with BMI range 18 - 34 kg/m
2
), a COC containing 30 µg 
ethinylestradiol (EE) and 3 mg drospirenone (DRSP) was used for 3 cycles, followed by 6 
cycles of the same COC combined with either 50 mg/day DHEA or placebo. Total T, 
albumin, sex hormone-binding globulin (SHBG), DHEA-sulfate (DHEA-S), 4-
androstenedione (AD), 3α-androstanediol glucuronide (ADG) and estradiol (E2) were 
measured, whereas free T and the free T index (FTI) were calculated. Assessments took place 
at baseline (no COC use), after the run-in period (COC use alone) and during the treatment 
period (DHEA or placebo). 
 
Results: During COC use alone androgen levels decreased, especially total T by 62% and 
free T by 86%, and SHBG increased by 243%. Total T increased with DHEA compared to 
placebo (change from end of run-in period to end of treatment period: 1.3±1.2 nmol/L vs 
0.0±0.4 nmol/L; P < 0.0001), and was restored to baseline levels. Free T and the FTI 
increased significantly (P < 0.0001), but the free T level was still 53% below baseline levels. 
DHEA-S, AD and ADG increased significantly to levels above baseline (P < 0.0001 for 
each). DHEA had no effect on SHBG, albumin and E2.  
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Conclusions: An EE/DRSP containing COC strongly suppressed endogenous androgen 
concentrations in all users. The addition of 50 mg DHEA to a COC regimen containing 
EE/DRSP restored total T to baseline levels, but free T levels were restored by only 47% as 
most of the T remains bound to SHBG.  
 
Implications: 
When using a COC that increases SHBG considerably, a daily dose of 50 mg DHEA is 
insufficient to normalize free T levels completely.  
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Introduction  
 
Combined oral contraceptives (COCs) reduce circulating androgen levels by inhibition of 
ovarian and adrenal androgen synthesis. In particular, the level of testosterone (T), the most 
potent female androgen, decreases by a mean of 31% [1]. In addition, the estrogenic 
component of COCs, ethinylestradiol (EE), stimulates hepatic sex hormone-binding globulin 
(SHBG) production considerably in a dose-dependent manner [1]. Because SHBG binds and 
inactivates T, there is further suppression of the free T concentrations (up to 61%) and the 
free androgen or T index (FAI or FTI), a measure of bioavailable T, is significantly reduced 
[1, 2]. 
T deficiency in women has been associated with a broad range of undesired effects [3, 
4], some of which, including mood disturbances and interference with sexual function, have 
been reported as side effects of COCs [5-8]. Normalizing total T and other androgen levels in 
women using a COC may be achieved by the co-administration of the natural human adrenal 
androgen dehydroepiandrosterone (DHEA), because it is orally bioavailable [9] and partially 
metabolized into T [10-12].  
In the present prospective study the effect of daily co-administration of 50 mg DHEA 
in new COC users was investigated. In this paper the effect on androgen and androgen-
related endocrine parameters will be reported. In a second paper the clinical effects on sexual 
function, mood, skin and safety will be reported [13].  
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Materials and Methods 
 
Study population 
Participants had to be healthy, sexually active, aged between 18 and 35 years, and have a 
body mass index (BMI) between 18 and 35 kg/m
2
. All participants must not have taken a 
hormonal contraceptive for at least 3 months prior to the start of the study medication. In 
addition, subjects were required to have a regular menstrual cycle of 25-35 days before the 
start of the study. Major exclusion criteria were contraindications for COC use; concomitant 
medication that might interfere with the metabolism of contraceptive steroids or DHEA; 
hyperandrogenism (free T levels ≥ 31.0 pmol/L), severe acne, severe hirsutism and polycystic 
ovarian syndrome based on ovarian ultrasound and/or the LH/FSH ratio. 
The study was approved by an independent ethics committee and was conducted in 
accordance with the Declaration of Helsinki and the ICH guideline for Good Clinical 
Practice. All participants gave written informed consent. The study has been registered at the 
International Standard Randomised Controlled Trial Number Register (no. 
ISRCTN06414473). 
 
Study design and procedures  
This randomized, double-blind, placebo-controlled, comparative, parallel-group study was 
conducted from November 2007 until November 2009 at the University Hospital 
Centre Hospitalier Régional (CHR) Citadelle, in Liège, Belgium. Prior to randomization, 
evidence of ovulation during a spontaneous menstrual cycle was documented by a midluteal 
progesterone level of  >4.77 nmol/L (1.5 ng/mL). Eligible participants were randomized to a 
30 µg EE and 3 mg drospirenone (DRSP) COC with co-administration of DHEA or placebo 
in a ratio of 1:1.  Although all COCs suppress androgens [1], the EE/DRSP COC was chosen, 
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because at the time of study it was one of the most prescribed contraceptive pills in Western 
Europe [14]. Blinded study medication was packed per subject number according to a 
computer-generated randomization list that was only known to an independent biostatistician. 
The study consisted of a 3 cycle run-in period with COC use alone, followed by a 6 
cycle treatment period in which participants continued COC use in combination with either 
DHEA or a placebo. Each treatment cycle consisted of 28 days. During all treatment cycles 
participants took one tablet of the EE/DRSP COC from day 1 to day 21 followed by a pill-
free period of 7 days. During the 6-cycle treatment period, DHEA or placebo was used 
continuously, including during the pill-free period.  
Study visits took place before the start of the COC during the luteal phase of the cycle 
(baseline), once every three cycles thereafter on cycle days 22-28 (cycle 3, cycle 6 and cycle 
9) and at a follow-up 7-14 days after the last intake of study medication. During these visits, 
blood samples were taken in the morning after an overnight fasting period before 
administration of study medication.  
The primary endpoint was the change in total T levels between the end of the run-in 
treatment period (cycle 3) and the end of the treatment period (cycle 9). Secondary objectives 
included the change in the following laboratory parameters during COC use only (baseline to 
end of the run-in period at cycle 3) and during the treatment period (end of the run-in period 
to cycle 6 and cycle 9): Total T, albumin, SHBG, free T, FTI, DHEA-sulfate (DHEA-S), 4-
androstenedione (AD), 3α-androstanediol glucuronide (ADG) and estradiol (E2).  
 
Study medication  
A dose of 50 mg DHEA was calculated to compensate for the loss of T induced by a COC, 
based on previous dose-finding studies with DHEA in elderly people [10], along with the 
magnitude of the decrease of T levels during COC use [1]. The DHEA and placebo tablets 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
AMUSA I Endo Tables 18 July 
were manufactured by Unither Pharmaceuticals (Le Haillan, France) and were identical in 
appearance. The commercially available COC Yasmin
®
 (Bayer Healthcare, Berlin) was used.  
 
Analytical assays and measurements  
Serum samples were sent to the laboratory of CHR Citadelle in Liege, Belgium for 
immediate analysis (albumin, SHBG, DHEA-S, E2) and for storage at -80°C until further 
analysis at the end of the study (T, AD, ADG). Total T (nmol/L) was measured by 
ImmuChem Double Antibody TESTOSTERONE 
125
I RIA Kit (ICN Biomedicals / MP 
Biomedicals). AD (nmol/L) and ADG (nmol/L) were analyzed using the Androstenedione-
RIA-CT and A-Diol Glucuronide-RIA-CT radioimmunoassay kits, respectively (DIAsource 
ImmunoAssays S.A.). Electrochemiluminescence immunoassays (Modular E170 analyser, 
Roche) were applied for measuring SHBG (nmol/L), DHEA-S (µmol/L) and E2 (pmol/L). 
Analysis of albumin was performed by an automated bromocresol green method on Modular 
system. The intra- and inter-assay coefficients of variance for the assays are shown in 
Supplemental Table 1. 
Free T (pmol/L) was calculated based on total T, SHBG and albumin (g/L) 
concentrations [15, 16]. The FTI (or FAI)) was calculated using total T and SHBG, according 
to the formula: FTI = 100 x [T]/[SHBG].  
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Statistical analysis 
A sample size calculation was carried out, which was based on the primary objective of the 
study to test the null hypothesis that 50 mg DHEA added to an EE/DRSP COC is able to 
significantly increase total T levels from the end of the run-in period to the end of the 
treatment period compared to placebo. Assuming that T levels would decline by at least one 
third of their value (33%) at the end of the run-in-period, that initial T levels would be 
completely restored (100%) after 6 cycles in the DHEA group and remain unchanged in the 
placebo group, at the 5% significance level and with a power of 90%, 37 participants were to 
be needed in each group to demonstrate a difference (total 74). Considering a 30% adjustment 
of sample sizes due to discontinuation and non-evaluable cycles, a minimum of 96 women 
were to be included in the study. Therefore, it was decided to randomize in total 100 
participants (50 per treatment group).  
Data analyses were based on an intention to treat approach. A log-transform was used 
to normalize the distribution of the variables if necessary. Within each treatment group 
(DHEA and placebo), changes between study visits were assessed for each variable using a 
paired t-test. When comparing these changes between the two groups (DHEA vs placebo), the 
unpaired t-test with unequal variances was used. Results were considered to be significant at 
the 5% level (P < 0.05). All calculations were carried out using SAS (Version 9.1 for 
Windows) and S-PLUS (Version 7.0) statistical packages.
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Results 
 
Study population characteristics  
A total of 142 women were screened, of which 99 were randomized and treated. The baseline 
characteristics of the study population were comparable between groups (Table 1). Only two 
women, both in the placebo group, discontinued early (Figure 1), one after 6 cycles for 
logistical reasons and one after 4 cycles at her own initiative because of hirsutism. All 
available data were included in the analyses. 
 
Endocrine parameters 
The effect of COC use alone on androgens and parameters related to androgen metabolism 
during the run-in period are shown in Table 2. At the end of the run-in period, a statistically 
significant decline of 62% was found for total T (P < 0.0001) (Table 2 and Figure 2). A large 
and statistically significant decrease of free T (86%) and the FTI (91%) was also observed 
(both P < 0.0001) (Table 2 and Figure 2). SHBG levels increased significantly (243%; 
P < 0.0001) (Table 2 and Figure 2). COC use alone resulted in statistically significant 
decreases in all the other parameters (Table 2). 
The effect of 50 mg DHEA plus COC compared to placebo plus COC on androgens 
and parameters related to androgen metabolism is shown in Table 2. Total T significantly 
increased in the DHEA group compared to the placebo group (change from end of run-in 
period to end of treatment period: 1.3±1.2 vs 0.0±0.4 nmol/L; P < 0.0001) (Table 2 and 
Figure 2). Statistically significant increases from the end of the run-in period to the end of the 
treatment period in the DHEA compared to the placebo group were also observed for free T, 
the FTI, DHEA-S, AD and ADG (Table 2; P < 0.0001 for each). The change from the end of 
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the run-in period to the end of the treatment period was not statistically significantly different 
between the DHEA and the placebo groups for SHBG, albumin and E2 (Table 2).  
The change and the relative change from baseline to the end of the treatment period is 
also shown in Table 2. Total T levels were restored to baseline levels in the DHEA group and 
remained low in the placebo group; the levels were significantly increased from baseline to 
the end of the treatment period in the DHEA group compared to placebo (0.3 nmol/L [relative 
change: 20%] vs -0.8 nmol/L [-52%]; P < 0.0001) (Table 2 and Figure 2). In the placebo 
group the free T levels and the FTI remained as low as at baseline and in the DHEA group 
they were still lower than at baseline, but were statistically higher than placebo (Free T: -10.3 
pmol/L [-53%] vs -15.2 pmol/L [-79%]; FTI: -2.1 [-66%] vs -2.5 [-88%]; both P < 0.0001) 
(Table 2 and Figure 2). The increased levels of SHBG observed during the run-in period were 
maintained at the same level in both treatment groups and there was no statistically 
significant difference between the groups (134.9 [234%] vs 140.7 [255%]) (Table 2 and 
Figure 2). DHEA-S, AD and ADG levels were restored to levels above baseline in the DHEA 
group but not in the placebo group (between group difference P < 0.0001 for each; Table 2). 
There were no statistically significant between group differences for albumin and E2; albumin 
levels remained relatively unchanged in both groups (relative change: -5% and -6%) and E2 
levels decreased from baseline in both groups (-75% and -71%).
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Discussion 
 
To our knowledge this is the first study aiming at restoring the levels of T during COC use. 
For this purpose we could have used e.g. a T-gel or a T-patch, but we have chosen to try to 
achieve normalization of T levels by daily co-administration of the oral T-precursor DHEA, 
since our goal is to develop a new oral contraceptive combination.  
The study was designed to create optimal conditions to evaluate first the effect of a 
COC only. Therefore only women who had not used hormonal contraception for at least 3 
months were included in the study and there was a 3-cycle run-in period with COC use alone 
prior to the DHEA/placebo treatment period. The observed qualitative changes of the 
(precursor) androgens and SHBG after COC use alone are in agreement with previous studies 
[1, 2, 17-21], but the quantitative suppression of total T and free T by 62% and 86%, 
respectively is more pronounced than reported in the literature previously (mean of 31% and 
61%, respectively) [1]. Importantly, all COC users experienced a decrease of their total and 
free T. 
By administering 50 mg/day DHEA total T was restored completely to baseline 
levels. However the decrease of the biologically active free T levels was restored by only 
47%. We hypothesize that this is caused by the increased binding of T due to the strong rise 
of SHBG (243%) caused by the COC. The progestin DRSP does not counteract the effect of 
the estrogen (EE) on SHBG and may even increase SHBG further due to its anti-androgenic 
properties. Also the radioimmunoassay used to measure total T itself may be sensitive to high 
SHBG levels [22]. Levels of total T, as well as its measurement, are critically influenced by 
the concomitant rise of SHBG, which occurs with most, but not all COCs; therefore total T 
levels during COC use may be unreliable to judge the androgen status. Studies aiming at 
restoration of T homeostasis during COC use need to take these issues into account [22]. 
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Although androgens including DHEA are known to decrease SHBG [23, 24], in the current 
study no significant decrease of SHBG was observed in the DHEA group, which may be due 
to the relatively low 50 mg dose of DHEA used. The precursor androgens DHEA-S, AD and 
ADG were restored to levels above baseline. This is not considered to be clinically relevant 
since these circulating androgen precursors are biologically inactive [25]. Overall, to 
normalize free T completely when using a DRSP containing COC, a higher dose of DHEA 
may be required. 
Accurate measurement of free T in blood of females is difficult [26, 27] due to the 
very low concentrations (35 – 700 pmol/L; [24]), especially in women using COCs [1]. 
Preferred methods for direct measurement of free T are the mass action equation and 
equilibrium dialysis [3, 28]. These methods are time-consuming and have several drawbacks, 
such as requirement of a large volume sample, dilution effects, complicated correction of 
volume changes and inherent limitations of tracer analog method [29]. Furthermore, the 
detection level of the available LC-MS/MS method was not low enough. Therefore, in this 
study free T was obtained by calculation based on total T, SHBG and albumin concentrations 
[15, 16], which has previously been demonstrated to be a reliable method and comparable to 
direct measurements [28, 30]. 
A small but significant lowering of albumin by COC use only has been observed in 
some [2, 31] but not all [32] earlier studies. In the current study neither the COC use only nor 
the addition of DHEA affected albumin levels. Because COCs inhibit follicular development, 
E2 levels decreased significantly during both treatments. Since oral DHEA is not only 
metabolized by the liver to T, but also to E2 [33], it is important to note that E2 levels did not 
increase with the low 50 mg dose of DHEA used in the current study.  
In conclusion, this study shows that an EE/DRSP containing COC strongly suppresses 
endogenous androgen concentrations in all users. Total T levels were restored completely to 
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baseline levels by adding 50 mg DHEA, but this was partly due to the strong increase of 
SHBG and thereby of biologically inactive SHBG-bound T, whereas the biologically active 
free T levels were restored by only 47%. The clinical effects of adding DHEA to this COC 
will be reported in a separate paper [13].   
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Figure 1.  Study design and subject disposition; * one discontinued after 6 cycles for logistical 
reasons and the second one after 4 cycles at her own initiative because of hirsutism; both in the 
placebo group 
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Figure 2.  Effect of COC use alone and of 50 mg DHEA daily co-administration on total T (nmol/L), 
SHBG (nmol/L) and free T (pmol/L) in women using a COC containing 30 μg ethinylestradiol and 3 
mg drospirenone. In these box plots, half of the data (percentile 25-75) is represented by the boxes. 
Dark dashed lines in the boxes indicate the median. T-bars from the boxes extend to the minimum 
and maximum. Stars are outliers, defined as values more than three times the height of the box.; 
N.S., not significant; T, testosterone; SHBG, sex hormone-binding globulin 
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Table 1.  Baseline characteristics of the study population (n=99) 
Parameter        DHEA 
      n = 49 
       Placebo 
      n = 50 
Age, years  23.9 ± 3.7   22.6 ± 3.9 
BMI, kg/m2  22.8 ± 4.0   21.7 ± 2.5 
Ethnic origin 
 Caucasian, n (%) 
 Black, n (%) 
 Asian, n (%) 
 Other, n (%) 
 
 46 (94)  
 2 (4) 
 1 (2) 
 0 
  
 47 (94)  
 2 (4) 
 1 (2) 
 0 
Endocrine parameters    
 Total Testosterone (nmol/L)  1.4 ± 0.7   1.4 ± 0.6 
 SHBG (nmol/L)  59.3 ± 21.1   58.0 ± 23.1 
 Albumin (g/L)  46.2 ± 2.3   46.8 ± 2.3 
 Free Testosterone (pmol/L)  19.6 ± 14.6   19.4 ± 12.7 
 Free Testosterone Index  3.1 ± 2.9   3.1 ± 2.8 
 DHEA-S (µmol/L)  4.9 ± 1.8   5.2 ± 1.9 
 Δ4-androstenedione (nmol/L)  8.5 ± 3.1   7.7 ± 2.2 
 3α-androstanediol (nmol/L)  14.7 ± 6.8   14.1 ± 5.7 
 Estradiol (pmol/L)  532.9 ± 332.1   516.3 ± 257.6 
Data expressed in mean ± standard deviation; BMI, body mass index; DHEA(-S), 
dehydroepiandrosterone(-sulfate); n, number of subjects  
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Table 2: Effect of COC use alone and of 50 mg DHEA daily co-administration compared to placebo on androgens and parameters related to androgen 
metabolism in women using a COC containing 30 μg ethinylestradiol and 3 mg drospirenone  
Variable Baseline End of run-in 
period (Cycle 3: 
COC only) 
Relative 
change from 
baseline 
Treatment Treatment 
period (Cycle 6) 
End of 
treatment 
period 
(Cycle 9) 
Change from end 
of run-in to end of 
treatment period† 
Change from 
baseline to end of 
treatment period 
Relative 
change from 
baseline 
Total testosterone (nmol/L)   
All (n=99) 1.4±0.6 0.6±0.4* -62% DHEA(n=49) 2.1±1.5 1.7±1.1 1.3±1.2** 0.3±1.1** 20% 
    Placebo (n=48) 0.8 ±1.5 0.6±0.4 0.0±0.4 -0.8±0.6 -52% 
SHBG (nmol/L)   
All (n=99) 58.4±22.4 199.3±64.5* 243% DHEA (n=49) 196.2±64.6 195.1±64.4 -7.4±69.6 134.9±57.5 234% 
    Placebo (n=48) 211.8±59.8 206.9±68.1 13.3±61.5 140.7±76.3 255% 
Albumin (g/L)   
All (n=99) 46.5±2.3 43.9±2.1* -6% DHEA (n=49) 43.9±2.4 43.8±2.0 0.1±1.6 -2.5±2.0 -5% 
    Placebo (n=48) 43.7±2.4 43.9±1.9 -0.2±2.1 -3.7±5.5 -6% 
Free testosterone (pmol/L)   
All (n=99) 19.5±13.6 2.8±2.4* -86% DHEA (n=49) 10.6±7.9 9.3±8.0 6.8±7.8** -10.3±13.1** -53% 
    Placebo (n=48) 3.6±5.8 3.0±2.8 -0.2±2.8 -15.2±9.2 -79% 
FTI   
All (n=99) 3.1±2.9 0.3±0.3* -91% DHEA (n=49) 1.2±0.9 1.1±1.0 0.8±1.0** -2.1±2.5** -66% 
    Placebo (n=48) 0.4±0.6 0.3±0.3 -0.0±0.4 -2.5±1.7 -88% 
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DHEA-S (µmol/L)   
All (n=99) 5.0±1.9 3.7±1.9* -26% DHEA (n=49) 10.1±4.9 9.3±4.9 5.9±4.5** 4.4±4.4** 88% 
    Placebo (n=48) 3.6±1.7 3.8±2.1 -0.3± 0.9 -1.4±1.4 -27% 
∆4-androstenedione (nmol/L)   
All (n=99) 8.1±2.7 5.4±2.1* -33% DHEA (n=49) 12.2±6.3 10.2±5.8 5.1±6.0** 1.7±6.0** 22% 
    Placebo (n=48) 6.3±2.2 5.5±2.5 -0.3±2.1 -2.2±2.5 -27% 
3α-androstanediol (nmol/L)   
All (n=99) 14.4±6.2 8.6±4.2* -40% DHEA (n=49) 22.8±13.2 19.5±9.3 10.9±8.3** 4.9±9.0** 34% 
    Placebo (n=48) 9.1±2.6 8.0±3.0 -0.8±2.9 -6.1±5.2 -42% 
Estradiol (pmol/L)   
All (n=99) 524.9±294.0 119.3±95.4 -77% DHEA (n=49) 117.1±107.3 140.2±98.2 11.3±142.2 -392.7±330.9 -75% 
    Placebo (n=48) 122.8±88.4 139.7±97.5 34.5±126.0 -372.8±281.8 -71% 
Data expressed in mean ± standard deviation; COC, combined oral contraception; DHEA(-S), dehydroepiandrosterone (-sulfate); FTI, free testosterone index; n= number of subjects; SHBG, 
sex hormone-binding globulin; bold*=P < 0.0001 between no COC (baseline) and COC use only (Cycle 3); bold**=P <0.0001 between-group difference; † Primary study objective 
